Nykode Therapeutics As (VACBF) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the NICO Therapeutics Q4 2025 financial results presentation. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation and you may ask a question at any time by typing it into the ask a question feature on your screen. As a reminder, this conference is being recorded. It's now my pleasure to introduce Chief Executive Officer Michael Ensign. Please go ahead, sir. Thank you very much, Kevin, and a very warm welcome to all participants at this quarterly presentation from NICODE, where we look forward to take you through the fourth quarter and achievements happening subsequent to the quarter. Just a quick reminder before we start of the forward-looking statement. We assume you are all familiar with these statements and that notice will move forward. Happy to, again, have with me here today in the room Aonita Frederiksen, our co-founder and chief scientific officer in health and business development. who will take us through a deeper dive on our status for the NEO program and our tolerance program, as well as Harald Guggen, our CFO, who will take you through the financial data towards the end of the presentation. Again, as a sort of recap, reminding everybody of our strategy, which we announced in August last year, a very clear and focused strategy on three different assets. through which we intend to build value in the near to long term for my code. Our lead asset is Abisuva, our HPV16 therapeutic immune therapy. which we are in the start-up phase of a randomized clinical trial called Ability in first-line recurrent metastatic NEC, and are on track to deliver meaningful interim results in 2027. Our second asset is VB2Neo, our individualized neoantigen therapy, where we are positioni...